ALS Therapy Development Institute
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Dec 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 2, 2026The maintenance fee for Method for the treatment of neurodegenerative diseases (US 9,044,459) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
- 2 fees due Jan 4 to 25, 2027 · next Jan 4
- 1 fee due Jul 2, 2027The maintenance fee for Inhibition of Dipeptide Repeat Proteins (US 11,857,534) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,435,514 | Method for the treatment of neurodegenerative diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,044,459 | Method for the treatment of neurodegenerative diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 8,673,308 | Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 8,946,301 | Targeting of T-Lymphocytes to Treat Amyotrophic Lateral Sclerosis In force · High confidence | In force | High confidence | |
| US 10,106,618 | ANTI-CD40L Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 10,683,356 | Methods of Treating a CD40L Associated Disease or Disorder by Administering ANTI-CD40L Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 11,014,990 | ANTI-CD40L Antibodies In force · Low confidence | In force | Low confidence | |
| US 11,692,040 | ANTI-CD40L Antibodies and Methods for Treating CD40L-RELATED Diseases or Disorders In force · Low confidence | In force | Low confidence | |
| US 12,275,793 | ANTI-CD40L Antibodies and Methods for Treating CD40L-RELATED Diseases or Disorders In force · Low confidence | In force | Low confidence | |
| US 11,384,152 | Therapeutic Anti-CD40 Ligand Antibodies In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 no status recorded